MedGene Therapeutics, Inc. is a T cell immunotherapy company whose primary goal is the treatment of solid tumor cancers. T cells are the body’s major natural defense against the tumors.. By extracting a patient’s active T cells, replicating & enriching them, then reinfusing the cells back into the patient’s bloodstream, we can enhance the body’s defenses against cancer. While T cell therapy has been available for over 30 years, scientists have been unable to achieve results with the treatment in solid tumors. We have licensed PBL-T from NIH, and developed RIV-8 as a collaboration with Seoul National University. These drugs are the result of years of development, and are the fundamental platform technologies for for MedGene Therapeutics.